Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

Purpose: Prostate-specific membrane antigen (PSMA) ligands targeting has shown promising results in staging of prostate cancer (PCa). The aim of present study was to evaluate the value of 18F-PSMA-1007 PET/CT in PCa patients with biochemical recurrence. Methods: 71 patients with PCa after radical pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xing Zhou, Xiao Jiang, Luzhou Liu, Xiaoxiong Wang, Chuan Li, Yutang Yao, Ying Kou, Jiaqi Shen, Taipeng Shen, Zeng Li, Shengke Yang, Shukui Zhou, Hong Liao, Zhifu Luo, Xiaoai Wu, Shirong Chen, Zhuzhong Cheng
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Prostate cancer Prostate-specific membrane antigen Biochemical recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/af6f41997c3d418ba478c5e2e4a71f83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:af6f41997c3d418ba478c5e2e4a71f83
record_format	dspace
spelling	oai:doaj.org-article:af6f41997c3d418ba478c5e2e4a71f832021-11-26T04:26:42ZEvaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy1936-523310.1016/j.tranon.2021.101292https://doaj.org/article/af6f41997c3d418ba478c5e2e4a71f832022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1936523321002837https://doaj.org/toc/1936-5233Purpose: Prostate-specific membrane antigen (PSMA) ligands targeting has shown promising results in staging of prostate cancer (PCa). The aim of present study was to evaluate the value of 18F-PSMA-1007 PET/CT in PCa patients with biochemical recurrence. Methods: 71 patients with PCa after radical prostatectomy (RP) were included in the present study. Median prostate-specific antigen (PSA) level was 1.27 ng/mL (range 0.01–67.40 ng/mL, n = 69). All patients underwent whole-body PET/CT imaging after injection of 333±38 MBq 18F-PSMA-1007. The distribution of PSMA-positive lesions was assessed. The influence of PSA level, androgen deprivation therapy and primary Gleason score on PSMA-positive finding and uptake of 18F-PSMA-1007 were evaluated. Results: 56 (79%) patients showed at least one pathological finding on 18F-PSMA-1007 PET/CT. The rates of positive scans were 50%, 80%, 100%, 100% among patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and >2.0 ng/mL, respectively. The median Gleason score was 8 (range 7–10), and higher Gleason score (≤7 vs. ≥8) leads to higher detection rates (58.3% (14/24) vs. 88.9% (32/36), P = 0.006). The median SUVmax of positive findings in patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and >2.0 ng/mL were 4.51, 4.27, 11.50 and 14.08, respectively. The median SUVmax in patients with PSA level >2.0 ng/mL was significantly higher than that in patients with PSA ≤2.0 ng/mL (14.08 vs. 6.13, P<0.001). Conclusion: 18F-PSMA-1007 PET/CT demonstrated a high detection rate for patients with a raised PSA level after radical prostatectomy even in patients with extremely low PSA level (eg. PSA level ≤0.5 ng/mL), which was essential for further clinical management for PCa patients.Xing ZhouXiao JiangLuzhou LiuXiaoxiong WangChuan LiYutang YaoYing KouJiaqi ShenTaipeng ShenZeng LiShengke YangShukui ZhouHong LiaoZhifu LuoXiaoai WuShirong ChenZhuzhong ChengElsevierarticleProstate cancerProstate-specific membrane antigenBiochemical recurrenceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTranslational Oncology, Vol 15, Iss 1, Pp 101292- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Prostate cancer Prostate-specific membrane antigen Biochemical recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Prostate cancer Prostate-specific membrane antigen Biochemical recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xing Zhou Xiao Jiang Luzhou Liu Xiaoxiong Wang Chuan Li Yutang Yao Ying Kou Jiaqi Shen Taipeng Shen Zeng Li Shengke Yang Shukui Zhou Hong Liao Zhifu Luo Xiaoai Wu Shirong Chen Zhuzhong Cheng Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
description	Purpose: Prostate-specific membrane antigen (PSMA) ligands targeting has shown promising results in staging of prostate cancer (PCa). The aim of present study was to evaluate the value of 18F-PSMA-1007 PET/CT in PCa patients with biochemical recurrence. Methods: 71 patients with PCa after radical prostatectomy (RP) were included in the present study. Median prostate-specific antigen (PSA) level was 1.27 ng/mL (range 0.01–67.40 ng/mL, n = 69). All patients underwent whole-body PET/CT imaging after injection of 333±38 MBq 18F-PSMA-1007. The distribution of PSMA-positive lesions was assessed. The influence of PSA level, androgen deprivation therapy and primary Gleason score on PSMA-positive finding and uptake of 18F-PSMA-1007 were evaluated. Results: 56 (79%) patients showed at least one pathological finding on 18F-PSMA-1007 PET/CT. The rates of positive scans were 50%, 80%, 100%, 100% among patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and >2.0 ng/mL, respectively. The median Gleason score was 8 (range 7–10), and higher Gleason score (≤7 vs. ≥8) leads to higher detection rates (58.3% (14/24) vs. 88.9% (32/36), P = 0.006). The median SUVmax of positive findings in patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and >2.0 ng/mL were 4.51, 4.27, 11.50 and 14.08, respectively. The median SUVmax in patients with PSA level >2.0 ng/mL was significantly higher than that in patients with PSA ≤2.0 ng/mL (14.08 vs. 6.13, P<0.001). Conclusion: 18F-PSMA-1007 PET/CT demonstrated a high detection rate for patients with a raised PSA level after radical prostatectomy even in patients with extremely low PSA level (eg. PSA level ≤0.5 ng/mL), which was essential for further clinical management for PCa patients.
format	article
author	Xing Zhou Xiao Jiang Luzhou Liu Xiaoxiong Wang Chuan Li Yutang Yao Ying Kou Jiaqi Shen Taipeng Shen Zeng Li Shengke Yang Shukui Zhou Hong Liao Zhifu Luo Xiaoai Wu Shirong Chen Zhuzhong Cheng
author_facet	Xing Zhou Xiao Jiang Luzhou Liu Xiaoxiong Wang Chuan Li Yutang Yao Ying Kou Jiaqi Shen Taipeng Shen Zeng Li Shengke Yang Shukui Zhou Hong Liao Zhifu Luo Xiaoai Wu Shirong Chen Zhuzhong Cheng
author_sort	Xing Zhou
title	Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
title_short	Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
title_full	Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
title_fullStr	Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
title_full_unstemmed	Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
title_sort	evaluation of 18f-psma-1007 pet/ct in prostate cancer patients with biochemical recurrence after radical prostatectomy
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/af6f41997c3d418ba478c5e2e4a71f83
work_keys_str_mv	AT xingzhou evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT xiaojiang evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT luzhouliu evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT xiaoxiongwang evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT chuanli evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT yutangyao evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT yingkou evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT jiaqishen evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT taipengshen evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT zengli evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT shengkeyang evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT shukuizhou evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT hongliao evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT zhifuluo evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT xiaoaiwu evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT shirongchen evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy AT zhuzhongcheng evaluationof18fpsma1007petctinprostatecancerpatientswithbiochemicalrecurrenceafterradicalprostatectomy
_version_	1718409921882488832

Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

Ejemplares similares